[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004016950D1 - Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung - Google Patents

Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung

Info

Publication number
DE602004016950D1
DE602004016950D1 DE602004016950T DE602004016950T DE602004016950D1 DE 602004016950 D1 DE602004016950 D1 DE 602004016950D1 DE 602004016950 T DE602004016950 T DE 602004016950T DE 602004016950 T DE602004016950 T DE 602004016950T DE 602004016950 D1 DE602004016950 D1 DE 602004016950D1
Authority
DE
Germany
Prior art keywords
breast cancer
cyclin
cancer treatment
ingredients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004016950T
Other languages
English (en)
Inventor
Asa Kronblad
Maria Stendahl
Goeran Landberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forskarpatent I SYD AB
Original Assignee
Forskarpatent I SYD AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forskarpatent I SYD AB filed Critical Forskarpatent I SYD AB
Publication of DE602004016950D1 publication Critical patent/DE602004016950D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004016950T 2003-01-15 2004-01-09 Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung Expired - Fee Related DE602004016950D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300098A SE0300098D0 (sv) 2003-01-15 2003-01-15 Use of cyclin D1 inhibitors
PCT/SE2004/000006 WO2004062654A1 (en) 2003-01-15 2004-01-09 Use of cyclin d1 inhibitors

Publications (1)

Publication Number Publication Date
DE602004016950D1 true DE602004016950D1 (de) 2008-11-20

Family

ID=20290133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016950T Expired - Fee Related DE602004016950D1 (de) 2003-01-15 2004-01-09 Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung

Country Status (6)

Country Link
US (1) US20060019883A1 (de)
EP (1) EP1583522B1 (de)
AT (1) ATE410155T1 (de)
DE (1) DE602004016950D1 (de)
SE (1) SE0300098D0 (de)
WO (1) WO2004062654A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1933818A (zh) 2004-01-30 2007-03-21 马尔斯公司 用于治疗癌症的方法和组合物
EP1743654A1 (de) * 2005-07-15 2007-01-17 TopoTarget Germany AG Verwendung von Histon Deacetylase-Hemmer zusammen mit NSAIDen zur Behandlung von Krebs und/oder Entzündungskrankheiten
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
WO2008013589A2 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
BRPI0720991A8 (pt) * 2006-12-29 2016-03-15 Gloucester Pharmaceuticals Inc Preparação da romidepsina
US20100093610A1 (en) * 2006-12-29 2010-04-15 Vrolijk Nicholas H Romidepsin-based treatments for cancer
US20100285002A1 (en) * 2008-01-04 2010-11-11 Immune Disease Institute, Inc. Treatment or prevention of inflammation by targeting cyclin d1
EP2288721B1 (de) * 2008-05-16 2014-05-21 Atlas Antibodies AB Behandlungsprognose mit imgcr-protein
JP5886743B2 (ja) 2009-07-31 2016-03-16 アメリカ合衆国 抗血管新生性低分子および使用方法
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120208872A1 (en) * 2011-02-11 2012-08-16 Taipei Medical University Use of tea polyphenols for treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer
TWI481398B (zh) * 2011-02-14 2015-04-21 Univ Taipei Medical 茶多酚用於治療及／或預防尼古丁或尼古丁衍生化合物或雌激素誘發之乳癌之用途
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2023211888A1 (en) * 2022-04-25 2023-11-02 Delta Next-Gene, LLC Methods of treating cancer by targeting drivers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4043900A (en) * 1999-03-30 2000-10-16 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors

Also Published As

Publication number Publication date
SE0300098D0 (sv) 2003-01-15
US20060019883A1 (en) 2006-01-26
EP1583522B1 (de) 2008-10-08
ATE410155T1 (de) 2008-10-15
EP1583522A1 (de) 2005-10-12
WO2004062654A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE312635T1 (de) Ventilanordnung
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE50310516D1 (de) Fredericamycin-derivate
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
MX2021015352A (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
ATE420099T1 (de) Medikament zur wachstumsinhibierung von tumoren
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE353650T1 (de) Kombinationstherapie zur behandlung von krebs
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee